These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

689 related items for PubMed ID: 11974560

  • 21. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy.
    Kim CJ, Min YK, Ryu WS, Kwak JW, Ryoo UH.
    Arch Intern Med; ; 156(15):1693-700. PubMed ID: 8694668
    [Abstract] [Full Text] [Related]

  • 22. Two-year prospective and comparative study on the effects of tibolone on lipid pattern, behavior of apolipoproteins AI and B.
    Castelo-Branco C, Casals E, Figueras F, Sanjuan A, Vicente JJ, Balasch J, Vanrell JA.
    Menopause; 1999; 6(2):92-7. PubMed ID: 10374214
    [Abstract] [Full Text] [Related]

  • 23. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N, Genazzani AD, Bernardi F, Casarosa E, Pieri M, Palumbo M, Picciarelli G, Gabbanini M, Luisi M, Genazzani AR.
    Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
    [Abstract] [Full Text] [Related]

  • 24. A 2-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin.
    Milner MH, Sinnott MM, Cooke TM, Kelly A, McGill T, Harrison RF.
    Obstet Gynecol; 1996 Apr; 87(4):593-9. PubMed ID: 8602314
    [Abstract] [Full Text] [Related]

  • 25. Short-term effects of hormone therapy on serum C-reactive protein levels in postmenopausal women.
    Kiran H, Kiran G.
    Arch Gynecol Obstet; 2006 Apr; 274(1):9-12. PubMed ID: 16369811
    [Abstract] [Full Text] [Related]

  • 26. Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women.
    Christodoulakos GE, Lambrinoudaki IV, Panoulis CP, Papadias CA, Kouskouni EE, Creatsas GC.
    Gynecol Endocrinol; 2004 May; 18(5):244-57. PubMed ID: 15346660
    [Abstract] [Full Text] [Related]

  • 27. Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women.
    Gambacciani M, Ciaponi M, Cappagli B, Genazzani AR.
    Am J Obstet Gynecol; 2001 Nov; 185(5):1180-5. PubMed ID: 11717654
    [Abstract] [Full Text] [Related]

  • 28. A comparative study of two hormone replacement therapy regimens on safety and efficacy variables.
    Siseles NO, Halperin H, Benencia HJ, Berg G, Pilnik S, Mesch V, Arrighi B, Wikinski RW.
    Maturitas; 1995 Apr; 21(3):201-10. PubMed ID: 7616869
    [Abstract] [Full Text] [Related]

  • 29. Assessment of DNA damage in postmenopausal women under hormone replacement therapy.
    Ozcagli E, Sardas S, Biri A.
    Maturitas; 2005 Jul 16; 51(3):280-5. PubMed ID: 15978971
    [Abstract] [Full Text] [Related]

  • 30. Efficacy comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study.
    Chandeying V, Sangthawan M.
    J Med Assoc Thai; 2007 Sep 16; 90(9):1720-6. PubMed ID: 17957910
    [Abstract] [Full Text] [Related]

  • 31. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels.
    Gol M, Akan P, Dogan E, Karas C, Saygili U, Posaci C.
    Maturitas; 2006 Feb 20; 53(3):252-9. PubMed ID: 15990257
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women.
    Hudita D, Posea C, Ceausu I, Rusu M.
    Eur Rev Med Pharmacol Sci; 2003 Feb 20; 7(5):117-25. PubMed ID: 15214586
    [Abstract] [Full Text] [Related]

  • 33. Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding.
    Yildirim G, Tugrul S, Uslu H, Pekin O, Eren S.
    Arch Gynecol Obstet; 2006 Feb 20; 273(5):268-73. PubMed ID: 16315025
    [Abstract] [Full Text] [Related]

  • 34. Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study.
    Chang TC, Lien YR, Chen M, Cheng SP, Chen RJ, Chow SN.
    Acta Obstet Gynecol Scand; 2004 Jul 20; 83(7):661-6. PubMed ID: 15225192
    [Abstract] [Full Text] [Related]

  • 35. Effects of long-term hormone treatment and of tibolone on monoamines and monoamine metabolites in the brains of ovariectomised, Cynomologous monkeys.
    Gibbs RB, Edwards D, Lazar N, Nelson D, Talameh J.
    J Neuroendocrinol; 2006 Sep 20; 18(9):643-54. PubMed ID: 16879163
    [Abstract] [Full Text] [Related]

  • 36. Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women.
    Christodoulakos GE, Lambrinoudaki IV, Creatsa MG, Economou EV, Siasou Z, Panoulis CP, Kalligerou I, Papadias C.
    Climacteric; 2008 Apr 20; 11(2):155-65. PubMed ID: 18365858
    [Abstract] [Full Text] [Related]

  • 37. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
    Christodoulakos GE, Botsis DS, Lambrinoudaki IV, Papagianni VD, Panoulis CP, Creatsa MG, Alexandrou AP, Augoulea AD, Dendrinos SG, Creatsas GC.
    Maturitas; 2006 Mar 20; 53(4):413-23. PubMed ID: 16140483
    [Abstract] [Full Text] [Related]

  • 38. Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women.
    Yang TS, Tsan SH, Chen CR, Chang SP, Yuan CC.
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 May 20; 62(5):308-15. PubMed ID: 10389286
    [Abstract] [Full Text] [Related]

  • 39. Effects of tibolone and conventional HRT on the expression of estrogen and progesterone receptors in the breast.
    Ma L, Hofling M, Masironi B, von Schoultz B, Cline JM, Sahlin L.
    Maturitas; 2008 Dec 20; 61(4):345-9. PubMed ID: 18980817
    [Abstract] [Full Text] [Related]

  • 40. Conjugated estrogen plus medroxyprogesterone does not impair blood rheological properties in hypertensive postmenopausal women.
    Sumino H, Ichikawa S, Takahashi T, Sakamoto H, Goto-Onozato K, Koya S, Kanda T, Nara M, Seki K, Murakami M, Kurabayashi M.
    Maturitas; 2006 Feb 20; 53(3):306-14. PubMed ID: 16040211
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.